HGS stock skyrockets on Glaxo deal talk

Talk is once again raging that GlaxoSmithKline is negotiating to buy Human Genome Sciences for some $4 billion. HGS, which makes an experimental lupus drug, saw its stock soar for the sixth straight day on rumors that Glaxo might make a $30-per-share-offer. Report